Figure 5. Preclinical validation of NIS functional augmentation by NaB and VPA treatment.
(A) Accumulation of 99mTc-pertechnetate in NIS-expressing tissues like thyroid, gastric mucosa (stomach) and MDA-MB-231 tumor xenografts pre- and post-NaB and VPA treatment was recorded by gamma camera imaging 20 minutes after radiotracer injection. Mice untreated or treated with lower dose of the candidate drugs i.e. 250 mg/kg for VPA and 500 mg/kg of NaB tested are represented. (B,C) Charts representing normalized 99mTc-pertechnetate uptake (count) measured from thyroid (B) and tumor (C) tissue of mice images untreated or treated with two different concentration of NaB. (D,E) Chart representing similar uptake values upon VPA treatment. F. Digital autoradiography images showing intra-tumor uptake of 125I at 4 hours after tracer injection. Images represent MDA-MB-231 tumor tissue sections which were grown on nude mice treated as vehicle control, VPA (250 mg/kg) and NaB (500 mg/kg) as marked. (G) ROI analysis from autoradiograph images above. The quantitative results are expressed as PSL/mm2 (mean ± SD) and *indicate p < 0.05.